We conducted a meta-analysis of 12 studies including 1,284 cancer patients and 10 distinct cancer types and found that BCYRN1 overexpression in the tumors correlated significantly to poor survival, worse clinical stage, distant tumor metastasis, and advanced tumor T stage with greater invasiveness. Here, BCYRN1 is linked to cancer.